Immunological Perspectives of sub-Saharan Populations under Prophylaxis against Malaria

2 authors:

George Msema Bwire
Muhimbili University of Health and Allied Sciences
7 PUBLICATIONS **1** CITATION

SEE PROFILE

Kennedy Mwambete
Muhimbili University of Health and Allied Sciences
42 PUBLICATIONS **460** CITATIONS

SEE PROFILE

Some of the authors of this publication are also working on these related projects:

Project   Antimicrobial resistance of otitis media associated bacteria from asymptomatic HIV patients View project

Project   Antimicrobial resistance View project

Immunological Perspectives of sub-Saharan Populations under Prophylaxis against Malaria

George M Bwire[1] * and Kennedy D Mwambete[1]

[1]Department of Pharmaceutical Microbiology, School of Pharmacy, Muhimbili University of Health and Allied Sciences, P.O. Box 65013 Dar es Salaam, Tanzania.

***Corresponding Author :** **George M Bwire**, Department of Pharmaceutical Microbiology, School of Pharmacy, Muhimbili University ofHealth and Allied Sciences,Tanzania. E-mail: **gbwire@muhas.ac.tz**

Abstract

Immunity is the state of protection against infectious disease conferred either through an immune response generated by immunization or previous infection. Generated immune responses may be long lasting even lifelong or gives immediate, but short-lived protection. In malaria-endemic areas, young children and pregnant women are particularly susceptible to malaria, but with exposures protective immunity against malaria develop although sterile immunity is never achieved. Assuring protection to vulnerable populations, prophylaxis against malaria is advocated to pregnancy women and sickle cell disease children. Unfortunately, prophylaxis has been suggested to cause a decrease in exposure that curtails the development of acquired protective immunity, leaving individuals more susceptible to malaria in future. To describe this event, a review on effects of intermittent preventive therapy in pregnant women primigravidae (first pregnancy) in particular and chemoprophylaxis against malaria in sickle cell disease children was conducted.

Keywords: acquired immunity; chemoprophylaxis; malaria endemic; pregnant women; sickle cell

Background

Malaria especially caused by *Plasmodium falciparum* is one of the leading cause of morbidity and mortality to vulnerable populations such as pregnant women and children under five years of age (1–3). According to World Health Organization (WHO) report of 2018, pregnancy women and children aged below five years contributed more than 80% of all malaria cases (3). Furthermore, malaria has been the mostly recorded infection in children with sickle cell disease (SCD) (4–9).

To ensure protection from the disease burden especially to vulnerable populations living in malaria endemic regions, WHO advocates the use of intermittent preventive therapy in pregnancy women (IPTp) during the second and third trimester (3–5) and use of chemoprophylaxis in SCD children (6,10–12). However, administering prophylaxis to these groups have been reported to impair the acquisition of natural immunity against the disease through decreased exposures, leaving individuals more susceptible to malaria and lack of background immunity to assist antimalarial drug efficacy (13–15).

Therefore, to acquire more knowledge on how prophylaxis affects the natural acquired immunity, a review was conducted to describe the mechanisms behind this phenomenon.

Immunity to malaria

Naturally immunity to falciparum malaria acquired following exposure to malaria parasites protects many people routinely infected by *Plasmodium falciparum* from disease burdens such as severe malaria (cerebral malaria and anaemia) and death (16).

During humans stage various mechanisms are involved in protection these include; anti-disease immunity, by giving protection against clinical disease, which affects the risk and degree of morbidity associated with a given parasite density; anti-parasite immunity, offering protection against parasitemia, which affects the density of parasites; and lastly premunition, by providing protection against new infections through maintaining a low-grade and mostly asymptomatic parasitemia (16,17,18).

In sub-Saharan Africa, most people are usually infected by *P. falciparum*, and the majority of infected adults rarely experience the burden of the disease (16), infected individuals remain asymptomatic while inhabiting parasites in their blood that could become lethal to a malaria naive individuals (19,20). In addition, as compared to children, adults are less affected with malaria, which adds to the evidences of a lower risk of clinical disease conferred to adults through acquired immune protection, which is not present to infants and still developing in young children (18).

Moreover, natural acquired immunity are compromised when the adults migrate from their routine infections and apparently results to a decreased/lose of their natural acquired immunity (21–23). Therefore malaria protection is partial and requires a continues exposure (staying in malaria endemic regions) to malaria parasites to be maintained (21).

Prophylaxis against malaria in pregnancy and SCD patients

Prophylaxis is recommended to save the populations, which bare more risks of malaria infections and their associated health consequences (19,20,24), these groups include but not limited to travellers (from naïve malaria country to malaria areas) (25–28), pregnancy women and sickle cell disease children (13,14,29–31). The current review will focus more on IPTp and chemoprophylaxis in SCD children (10-12).

Intermittent preventive therapy in pregnancy

Pregnant women is a group mostly affected with malaria after children under age of five years (3), for the past decade pregnant women living in malaria endemic region are recommended to take sulfadoxine-pyrimethamine (SP) during the second and third trimesters (3,5) and this has been part of the national malaria control policy in 33 of 45 African countries where malaria is endemic (32). Evidence from studies reported that children born with mothers used IPTp-SP were protected from adverse effects of malaria such as maternal anemia, stillbirth, miscarriage, premature delivery, and low birth weight (32,33). Therefore pregnant women regardless of the presence or absence of malaria living in areas of moderate to high malaria transmission should be treated with at least two curative doses of SP with an interval of at least 1 month between the two doses, starting in the second trimester of pregnancy (14,32).

In addition, current recommendations from WHO to its member states advocates the minimization of these adverse effects through case management and malaria prevention using insecticide- treated bed nets (3,32,34).

Chemoprophylaxis in SCD patients

Sickle-cell trait (SCT) confers partial protection against malaria while homozygote SCD patients are at greater risk of malaria infection because once the infection occur is always severe (35), hence the use of malaria chemoprophylaxis in SCD patients especially children living in malaria endemic region is recommended (36). Unlike IPTp-SP use where it has been universally recommended, information on use of chemoprophylaxis in SCD children has remained to be scarce (3) i.e. Tanzania is a third leading country in sub-Saharan Africa after Nigeria and Congo with high number of SCD (7,12), still there is no functioning policy which guide the use of chemoprophylaxis against malaria in SCD patients, children in particular (37,38). However, some sub-Saharan African countries still advocates the use of chemoprophylaxis in SCD children (6,11,12).

Immunological consequences as a result of IPTp use

Despite the reported health benefits to babies born with mothers used IPTp-SP during pregnancy (32,33), this good intention has been reported to compromised the development of natural protective immunity especially in primigravidae (13,14,29).

P. falciparum is capable of inhabiting the placenta by expressing variant surface antigens (VSA) which results to a so-called pregnancy associated malaria (PAM) (39). Expressed VSA has good affinity to protein such as chondroitin sulfate A in the placental intervillous space (40,41). Exposure to this VSA proteins cause the development of natural acquired protective immunity to PAM and primigravidae are therefore particularly susceptible to PAM (39,42). However, giving IPTp to primigravidae prevent the acquisition of protective PAM immunity (13).

Although information is scarce but evidence from the current study conducted in Kenyan women found that primigravidae received IPTp-SP had significantly lower levels of VSA-PAM immunoglobulin G (IgG) than those women received a placebo. Furthemore, this study found an association between IPTp doses received and VSA-PAM-specific IgG levels and low IgG levels were recorded among multidose recipients (14). Support from the study by Rogerson et al 2007, pregnant women lacked immunity to this pregnancy-specific VSA protein rendered them susceptible to PAM (43). Other studies documented that, levels of VSA-PAM specific IgG increase with parity and are associated with protection against placental parasitemia, low birth weigh, and anemia (39,42).

Immunological consequences for using chemoprophylaxis

If SCT heterozygotes are protected from malaria through i) the establishment of blood-stage infection, ii) the development of high densities of parasites, iii) the progression of infection to symptomatic malaria (44), unfortunately, this is not the case to sickle cell anemia (SCA) individuals (35). One important reason is that malaria will make the anemia of SCA more severe, to the point of it becoming life-threatening; another reason is that spleen which normally plays great roles in filtering and removing parasitized red blood cells is often impaired in its functions in patients with SCA (35).

Both innate and acquired mechanisms protect children with sickle cell from malaria and this provide an evidence that SCT heterozygotes in malaria endemic areas have an increased probability of surviving until acquired immunity is sufficient to protect them, and others, regardless of their hemoglobin status (44,45).

However, acquisition of protective immunity can be compromised by the use of chemoprophylaxis. Although information regarding the effect of malaria chemoprophylaxis for development of acquired immunity is scarce in SCD but evidence from review on penicillin prophylaxis to prevent pneumococcal infection in SCD children indicated.

That rate from infection has been reduced following penicillin prophylaxis but a there was a concern on altered immunological response and penicillin-resistant Streptococcus pneumoniae (46).

Conclusions

A successful regime of intermittent preventive therapy in pregnancy especially primigravidae shield the exposure to placental malaria. More importantly, with reduced exposure to placental malaria, primigravidae might not produce antibodies or develop memory B cells to VSA-PAM. Additionally, if intermittent preventive treatment in pregnancy curtails development of specific immunity, susceptibility to placental malaria could extend to women in their second and even subsequent pregnancies and later to their children during the first year of life due to lack of passive acquired immunity. Furthermore, use of IPTp would results into a compromised background immunity to assist antimalarial drug efficacy.

On the other hand, SCD children and pregnant women especially primigravidae from sub-Saharan Africa countries who live in areas with low malaria transmission, other approaches such as case management and malaria prevention using insecticide- treated bed nets should be prioritized to save the purpose of acquisition of natural protective immunity which has the sustainable health consequences.

Moreover, this review recommends further follow-up studies to be conducted on the effect of protective acquired immunity in the populations under prophylaxis. For the mean time malaria vaccination programme particularly to vulnerable populations should be advocated.

Abbreviations

IgG: Immunoglobulin G; IPTp: Intermittent Preventive Therapy in Pregnancy; PAM: Pregnancy Associated Malaria; SCD: Sickle Cell Disease; SCT: Sickle Cell Trait; SP: Sulfadoxine Pyrimethamine; VSA: Variant Surface Antigens.

Acknowledgments

References

1. Bwire GM, Majigo M, Makalla R, Nkinda L, Mawazo A, et al. 2019. Immunoglobulin G responses against falciparum malaria specific antigens are higher in children with homozygous sickle cell trait than those with normal hemoglobin. BMC Immunol: 1–8.

2. Kilonzi M, Minzi O, Mutagonda R, Sasi P, Kamuhabwa A, et al. 2019. Comparison of malaria treatment outcome of generic and innovator's anti-malarial drugs containing artemether–lumefantrine combination in the management of uncomplicated malaria amongst Tanzanian children. Malar J . 18(1):133.

3. https://www.who.int/malaria/en/

4. Feng G, Simpson JA, Chaluluka E, Molyneux ME, Rogerson SJ. 2010. Decreasing burden of malaria in pregnancy in malawian women and its relationship to use of intermittent preventive therapy or bed nets. PLoS One;5(8).

5. Marealle AI, Mbwambo DP, Mikomangwa WP, Kilonzi M, Mlyuka HJ, et al. 2018. A decade since sulfonamide-based anti-malarial medicines were limited for intermittent preventive treatment of malaria among pregnant women in Tanzania. Malar J;17(1):1–7.

6. Oniyangi O, Omari AA. 2006. Malaria chemoprophylaxis in sickle cell disease. Cochrane Database Syst Rev; (3).

7. Kamugisha E, Peck RN, Saidi H, Smart LR, Kamugisha E, et al. 2016. Complications of sickle cell anaemia in children in Northwestern Tanzania Complications of sickle cell anaemia in children in Northwestern Tanzania. Hematology;(2).

8. Makani J, Komba AN, Cox SE, Oruo J, Mwamtemi K, et al. 2016. Malaria in patients with sickle cell anemia : burden , risk factors , and outcome at the outpatient clinic and during hospitalization;115(2):1–3.

9. Sadarangani M, Makani J, Komba AN, Ajala-agbo T, Newton CR, et al. 2009. An observational study of children with sickle cell disease in Kilifi , Kenya; 675–82.

10. Olaosebikan R, Ernest K, Bojang K, Mokuolu O, Rehman AM, et al. A 2015. A Randomized Trial to Compare the Safety, Tolerability, and Effectiveness of 3 Antimalarial Regimens for the Prevention of Malaria in Nigerian Patients with Sickle Cell Disease. J Infect Dis;212(4):617–25.

11. Williams TN, Obaro SK. 2011. Sickle cell disease and malaria morbidity: A tale with two tails. Trends Parasitol.;27(7):315–20.

12. Makani J, Williams TN, Marsh K. 2007. Sickle cell disease in Africa: burden and research priorities. Ann Trop Med Parasitol;101(1):3–14.

13. Rogerson S J, Hviid L, Duffy P E, Leke R F, Taylor D W. 2007. Malaria in pregnancy: pathogenesis and immunity. Lancet Infect Dis.; 7:105–17.

14. Staalsoe T, Shulman CE, Dorman EK, Kawuondo K, Marsh K. 2004. Intermittent preventive sulfadoxine-pyrimethamine treatment of primigravidae reduces levels of plasma immunoglobulin G, which protects against pregnancy-associated Plasmodium falciparum malaria. Infect Immun.;72(9):5027–30.

15. Paul D. Prinsen Geerligs, Bernard J. Brabin TAE. 2003. Analysis of the effects of malaria chemoprophylaxis in children on haematological responses, morbidity and mortality ;81:205–216.

16. Doolan DL, Dobaño C, Baird JK. 2009. Acquired immunity to Malaria. Clin Microbiol Rev.;22(1):13–36.

17. Red H, Ii C, Cell R, Bienzle IGU, Luzzattot L. 1981. Plasmodium Falciparum Malaria and human red cells. II. Red cell genetic traits and resistance against malaria; 10(1):16–22.

18. Schofield L, Mueller I. 2006. Clinical immunity to malaria. Curr Mol Med.;6(2):205–21.

19. Patouillard E, Griffin J, Bhatt S, Ghani A, 2017. Cibulskis R. Global investment targets for malaria control and elimination between 2016 and 2030. BMJ Glob Heal. May 1;2(2)

20. Bhatt S, Ghani AC, Patouillard E, Cibulskis RE, Gething PW, et al. 2016. Potential for reduction of burden and local elimination of malaria by reducing Plasmodium falciparum malaria transmission: a mathematical modelling study. Lancet Infect Dis;16(4):465–72.

21. Wipasa J, Suphavilai C, Okell LC, Cook J, Corran PH, et al. 2010. Long-Lived Antibody and B Cell Memory Responses to the Human Malaria Parasites , Plasmodium falciparum and Plasmodium vivax.;6(2).

22. Idris Z, Chan CW, Mohammed M, Kalkoa M, Taleo G, et al. 2010. Serological measures to assess the efficacy of malaria control programme on Ambae Island , Vanuatu. 2017;1–12.

23. Drakeley CJ, Corran PH, Coleman PG, Tongren JE, Mcdonald SLR, et al. Estimating medium- and long-term trends in malaria transmission by using serological markers of malaria exposure. 2005;102(14).

24. Soldin OP, Bierbower LH, Choi JJ, Choi JJ, Savannah Thompson-Hoffmanc,. Soldin. 2003. NIH Public Access. 2013;342(0):211–7.

25. Loutan L. 2003. Malaria: Still a threat to travellers. Int J Antimicrob Agents.;21(2):158–63.

26. B. H, P.D. C, D. C, H.D. N, D. O, et al. 2000. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: A randomised, double-blind study. Lancet.;356(9245):1888–1894.

27. Bijker EM, Bastiaens GJH, Teirlinck AC, van Gemert G-J, Graumans W, 2013. et al. Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity. Proc Natl Acad Sci U S A.;110(19):7862–7.

28. Friesen J, Silvie O, Putrianti ED, Hafalla JCR, Matuschewski K, 2010. Natural immunization against malaria: Causal prophylaxis with antibiotics. Sci Transl Med;2(40).

29. Desowitz RS. 1988. Prenatal immune priming in malaria: Antigen-specific blastogenesis of cord blood lymphocytes from neonates born in a setting of holoendemic malaria. Ann Trop Med Parasitol;82(2):121–5.

30. Ofori MF, Staalsoe T, Bam V, Lundquist M, David KP, et al. 2003. Expression of Variant Surface Antigens by Plasmodium falciparum Parasites in the Peripheral Blood of Clinically Immune Pregnant Women Indicates Ongoing Placental Infection. Society;71(3):1584–6.

31. England TN. 2000. Increased susceptibility to malaria during the early postpartum period.;343.

32. Nyunt MM, Adam I, Kayentao K, Van Dijk J, Thuma P, et al. 2010. Pharmacokinetics of sulfadoxine and pyrimethamine in intermittent preventive treatment of malaria in pregnancy. Clin Pharmacol Ther;87(2):226–34.

33. Guyatt HL, Snow RW. 2001. Malaria in pregnancy as an indirect cause of infant mortality in sub-Saharan Africa. Trans R Soc Trop Med Hyg;95(6):569–76.

34. White NJ. 2005. Intermittent presumptive treatment for malaria: A better understanding of the pharmacodynamics will guide more rational policymaking. PLoS Med;2(1):0028–33.

35. Luzzatto L. 2012. Sickle Cell Anaemia and Malaria.

36. Oniyangi O, Aaa O. 2009. Malaria chemoprophylaxis in sickle cell disease ;(1).

37. The united republic of Tanzania standard treatment guidelines and essential medicines list. 2013;

38. President ' s Malaria initiative Tanzania, Malaria Operational Plan FY 2018. 2018;

39. Staalsoe T, Shulman CE, Bulmer JN, Kawuondo K, Marsh K, et al., 2004. Variant surface antigen-specific IgG and protection against clinical consequences of pregnancy-associated Plasmodium falciparum malaria. Lancet.;363(9405):283–9.

40. Rogerson BSJ, Chaiyaroj SC, Ng K, Reeder JC, Brown G V. 1995. Plasmodium falciparum-infected;182(July).

41. Fried and P.E. Duffy M. 1996. Adherence of Plasmodium falciparum to chondroitin sulfate A in the human placenta. Sci 272 1502-4.;272(June):4–6.

42. Duffy PE, Fried M. 2003. Antibodies That Inhibit. Society. 71(11):6620–3.

43. Rogerson SJ, Mwapasa V, Meshnick SR. 2007. Malaria in pregnancy: Linking immunity and pathogenesis to prevention. Am J Trop Med Hyg.;77:14–22.

44. Gong L, Maiteki-Sebuguzi C, Rosenthal PJ, Hubbard AE, Drakeley CJ, et al. 2012. Evidence for both innate and acquired mechanisms of protection from Plasmodium falciparum in children with sickle cell trait. Blood.;119(16):3808–14.

45. Gong L, Parikh S, Rosenthal PJ, Greenhouse B. 2013. Biochemical and immunological mechanisms by which sickle cell trait protects against malaria. Malar J;12.

46. Phelps MPC and SJ. 2010. Penicillin prophylaxis in children with sickle cell disease. J Pediatr Pharmacol Ther;15(3):152–9.